Setting: Trial of Cefoxitin and Doxycycline versus
|
|
- Noel Walters
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1991, p /91/ $02.00/0 Copyright 1991, American Society for Microbiology Vol. 35, No. 8 Treatment of Acute Pelvic Inflammatory Disease in the Ambulatory Setting: Trial of Cefoxitin and Doxycycline versus Ampicillin- Sulbactam MARILOU KOSSEIM,1 ALLAN RONALD,"2 FRANCIS A. PLUMMER,"2'3 LORDES D'COSTA,4 AND ROBERT C. BRUNHAMl 2* Department of Medical Microbiology' and Medicine,2 University of Manitoba, Winnipeg, Manitoba R3E OW3, Canada, and Department of Medical Microbiology, University of Nairobi,3 and Nairobi City Council,4 Nairobi, Kenya Received 21 November 1990/Accepted 26 April 1991 Ampicillin-sulbactam (750 mg) given orally twice daily for 10 days was evaluated for the treatment of acute pelvic inflammatory disease (PID) in an ambulatory setting in Nairobi, Kenya. The first 26 women received ampicillin-sulbactam in an open-label fashion, and the remaining 75 women were randomly selected to receive either ampicillin-sulbactam (n = 38) or cefoxitin (2 g) intramuscularly and probenecid (1 g) orally, followed by doxycycline (100 mg) orally twice daily for 10 days (n = 37). Women were enrolled in a sexually transmitted disease clinic and were followed for clinical and microbiologic responses at 1 to 2 weeks and 4 to 6 weeks posttreatment. Women had a later follow-up visit to note interim pregnancy or underwent hysterosalpingography for fertility outcome assessment. The short-term clinical response rates were 70% for ampicillinsulbactam and 72% for cefoxitin-doxycycline (P = 0.47). Among Chlamydia trachomatis-infected women treated with ampicillin-sulbactam, three had microbiologic relapse. The post-pid tubal obstruction rates were similar in the two groups: 18% for ampicillin-sulbactam and 33% for cefoxitin-doxycycline (P = 0.31). Neither regimen was highly effective as a therapy for acute PID. These data strongly argue that primary prevention must be the goal for a reduction of PID morbidity and show that improved therapy for the treatment of PID in the ambulatory setting is needed. Acute pelvic inflammatory disease (PID) is a frequent infection of women of reproductive age. In 1982 in the United States, 14% of women of reproductive age reported that they had been treated at least once for PID (1). In developing countries, acute PID appears to be even more common, although accurate statistics are unavailable. Despite the fact that most women with acute PID are treated as outpatients, nearly all data regarding the treatment of acute PID is based on the treatment of hospitalized patients (19). The 1989 United States Public Health Services guidelines for the treatment of acute PID in outpatients recommend giving cefoxitin (2 g) intramuscularly and probenecid (1 g) orally, followed by the administration of doxycycline orally twice daily for 10 to 14 days, or an identical regimen except that ceftriaxone (250 mg given intramuscularly) is substituted for cefoxitin (19). A recent trial of the cefoxitin-probeneciddoxycycline combination reported that 22 of 24 women (92%) treated as outpatients responded clinically (27). This regimen is also recommended by the World Health Organization Expert Committee for the treatment of outpatient PID in developing countries (25). Since no studies with this regimen have been performed in developing countries, there is concern that a single dose of cefoxitin followed by an extended course of doxycycline may not be sufficient for the treatment of gonococcal or polymicrobial tubal infection in geographic regions where tetracycline-resistant pathogens are frequent. This may be the case for many areas of the developing world (16). Alternate regimens using drugs given orally which are well absorbed and can be prescribed for extended periods may more reliably treat the broad range of pathogens that cause acute PID. P-Lactamase inhibitors * Corresponding author such as clavulanic acid or sulbactam combined with amoxicillin or ampicillin have yielded excellent clinical cure rates among patients with PID in several trials performed in industrialized countries (19). In one trial, 95% of 100 hospitalized women with laparoscopically confirmed PID were clinically cured with parenterally administered amoxicillinclavulanate (17). Five trials with ampicillin-sulbactam regimens comprising over 118 patients with acute PID yielded cure rates between 86 and 95% (5, 10, 13, 14, 17). These regimens appear to be particularly effective for women with pyosalpinx or tubal abscess, a group known to have a slow response to antimicrobial therapy and a poor reproductive outcome (7, 14). Bruhat et al. (4) reported a small clinical trial that compared the efficacies of parenterally administered ampicillin-sulbactam and cefoxitin in the treatment of 40 women with laparoscopically confirmed acute salpingitis. Twenty-two women (55%) had chlamydial infection (and received supplemental doxycycline) and 8 women (20%) had pyosalpinx or tubal abscess. The trial was useful because it included posttreatment laparoscopy to evaluate pelvic inflammation and tubal patency. Women treated with ampicillin-sulbactam had significantly less severe peritoneal adhesions. One of 20 women treated with ampicillin-sulbactam, versus 6 of 20 women treated with cefoxitin, had severe peritoneal adhesions as determined by a second laparoscopy (P = 0.09). We were interested in comparing an oral form of ampicillin-sulbactam with cefoxitin-probenecid-doxycycline in the treatment of women with acute PID diagnosed in a sexually transmitted disease clinic in Nairobi, Kenya. We evaluated clinical and microbiologic responses to therapy at days 14 to 21 and days 35 to 42 posttherapy. Women also had later (6 to 12 weeks) posttreatment evaluation of reproductive outcome. Reproductive outcome measurement consisted of
2 1652 KOSSEIM ET AL. noting interim pregnancy or tubal patency as assessed by hysterosalpingography. We chose to use hysterosalpingography on the basis of the results reported by Falk (12) that an abnormal hysterosalpingogram with bilateral tubal obstruction was highly predictive of post-pid tubal infertility. MATERIALS AND METHODS Recruitment and evaluation of patients. Between February 1987 and March 1988, women attending a sexually transmitted disease clinic in Nairobi, Kenya were screened for inclusion in the study. Nonpregnant women complaining of the acute onset of lower abdominal pain who were not being treated with antibiotics and denied having allergies to the study drugs were evaluated. The study was reviewed and approved by the Institutional Review Board, and women were enrolled after giving informed consent. Acute PID was determined to be the most likely clinical diagnosis if pelvic examination revealed mild to moderate tenderness elicited by movement of the cervix and by bimanual palpation of the uterus and adnexa by the examining gynecologist (M.K.). The severity of pelvic organ tenderness was graded as follows: 0, no pain when examined; 1+, no reaction when examined, but the patient admitted to pain when questioned; 2+, grimaced with pain when examined; 3+, vocalized pain when examined; and 4+, bent over with pain prior to examination (17). Patients were enrolled if the findings of pelvic tenderness were graded at 2+ or greater at the initial examination. Women with signs of pelvic peritonitis or with a tender, indurated, fixed adnexal mass of greater than 6 cm were not enrolled and were referred to a hospital for inpatient care. At enrollment, demographic data, gynecologic, obstetric, surgical, contraceptive, and sexual histories and physical findings were recorded on a standard form. Two endocervical swabs were collected for the culture of Neisseria gonorrhoeae and Chlamydia trachomatis. Serum was collected for the determination of human immunodeficiency virus (HIV) type 1 antibody. Patients were assigned to one of two treatment regimens: (i) ampicillin-sulbactam (750 mg) given orally twice daily for 10 days or (ii) cefoxitin (2 g) given intramuscularly and probenecid (1 g) given orally, followed by the administration of doxycycline (100 mg) twice daily for 10 days. The first 26 subjects received ampicillin-sulbactam in an open-label fashion, and the remaining 75 women were selected by using a predetermined random number table to receive ampicillinsulbactam or cefoxitin-doxycycline. Both the patient and the clinician knew which study drug was allocated. Women were instructed to return at any time in the course of treatment or follow-up if symptoms recurred. Otherwise, they were seen approximately 1 and 4 weeks following the completion of treatment. Subjects were asked to abstain from sexual intercourse until the completion of the evaluation. Women were encouraged to have their sex partner(s) attend the clinic for investigation and epidemiologic treatment. At the follow-up visits, women were questioned about symptoms; adverse effects such as rash, diarrhea, nausea, and vomiting; sexual reexposure; and therapeutic compliance. Physical examination was repeated, and endocervical swabs were obtained for N. gonorrhoeae and C. trachomatis cultures. Clinical response to treatment was determined as follows. At the first follow-up, women were classified as clinically well, clinically improved, or unimproved. They were classified as clinically well if pelvic tenderness had completely resolved (i.e., grade 0 at examination), as clinically improved if findings were reduced to grade 1+ at examination ANTIMICROB. AGENTS CHEMOTHER. and they did not require additional antimicrobial therapy, and as clinically unimproved if the severity of the signs persisted at grade 2+ or greater and they required additional antimicrobial treatment. All women with findings of grade 2+ or greater were treated with antimicrobial agents. At the second follow-up visit, women were classified in the same manner. Women were assessed for fertility outcome after the 6-week follow-up visit. The date of last normal menses was determined, and a pregnancy test was done if pregnancy was suspected. If women were nonpregnant, hysterosalpingography was performed in order to evaluate tubal anatomy and patency after obtaining informed consent. Doxycycline prophylaxis was given during hysterosalpingography as recommended (20). Women who had bilaterally dilated (.11 mm) fallopian tubes which failed to spill dye into the peritoneal cavity were considered to have tubal occlusion. Microbiologic procedures. Specimens to be tested for N. gonorrhoeae were inoculated directly onto modified Thayer- Martin medium. N. gonorrhoeae was identified by colony appearance, Gram stain, and oxidase reaction. Specimens to be tested for C. trachomatis were stored in sucrose-phosphate transport medium at -70 C until they were cultured on cycloheximide-treated McCoy cells. Inclusions were idehntified by staining with fluorescein-conjugated monoclonal antibodies (21). HIV antibody testing was performed with a commercially available enzyme immunoassay (HTLV-III enzyme-linked immunosorbent assay (ELISA); Dupont DeNemours, Geneva, Switzerland). Positive ELISAs were repeated and confirmed by immunoblotting (HTLV-III Western blot; Dupont DeNemours) (9). Statistical analysis. The chi-square or Fisher's exact test was used for the statistical analysis of nominal, discrete variables. Statistical comparisons of the means were made by using Student's t test. RESULTS Study population. A total of 101 women were enrolled in the study; 26 received ampicillin-sulbactam in an open-label fashion, and 75 received randomized therapy (38 received ampicillin-sulbactam and 37 received cefoxitin-doxycycline). The treatment groups were similar in baseline characteristics, including age, parity, contraception practices, prior history of PID, duration of symptoms prior to presentation, and the finding of an adnexal mass at bimanual examination (Table 1). Overall, 83 of the enrolled women (82%) were seen at the follow-up visit 2 to 3 weeks after treatment, and 63 (62%) were seen at the follow-up visit 5 to 6 weeks after treatment (Table 1). Results of open-label study. Twenty-six consecutive women were treated with ampicillin-sulbactam, including 7 women with N. gonorrhoeae, 2 with C. trachomatis, 2 with both N. gonorrhoeae and C. trachomatis, and 15 with neither pathogen. Two women had palpable adnexal masses. Three women (12%) were seropositive for HIV. Sixteen of 18 women (89%) seen at early follow-up were clinically cured. One persistent and one recurrent gonococcal infection and two late relapsed chlamydial infections were observed. None of eight evaluable women had an adverse reproductive outcome. On the basis of these data, a randomized comparative trial of ampicillin-sulbactam versus cefoxitin-doxycycline was initiated. Randomized clinical trial. Thirty-eight women were randomly selected to receive ampicillin-sulbactam, and 37 women were randomly selected to receive cefoxitin-doxycy-
3 VOL. 35, 1991 TREATMENT OF PID 1653 TABLE 1. Selected characteristics in the treatment groups Value for group Randomized Characteristic Nonrandom, ampicillin-sulbactam Ampicillin-sulbactam Cefoxitin- (n 26) (n=38) doxycycline (n=37) Mean age (yr) ± SD 22.7 ± ± ± 5.1 Mean no. of lifetime sexual partners ± SD 10.8 ± ± ± 29.6 Mean gravidity ± SD 2.4 ± ± ± 2.0 Mean parity ± SD No. (%) pregnant in the prior 18 months 10 (38) 10 (32) 13 (35) No. (%) using no contraception 12 (46) 22 (58) 24 (63) Current contraception: Oral contraception Intrauterine device Depo-Provera Diaphragm, condoms, spermicides Tubal ligation No. (%) ever used intrauterine device 6 (23) 6 (17) 6 (16) Past history of STD' 9 (35) 12 (33) 11 (30) Past history of PID 3 (12) 4 (11) 8 (22) Mean duration of symptoms prior to 7.2 ± ± ± 24.5 presentation (days) ± SD Palpable adnexal mass 2 (8) 1 (3) 5 (14) No. (%) seen at 2- to 3-wk follow-up 18 (69) 33 (92) 32 (86) No. (%) seen at 5- to 6-wk follow-up 10 (38) 25 (69) 28 (76) No. (%) with fertility assessment 9 (35) 20 (53) 29 (78) a STD, sexually transmitted diseases; these included gonorrhea, syphilis, genital ulcer disease, and PID. cline. Twenty-seven of the 38 women (71%) treated with ampicillin-sulbactam had N. gonorrhoeae and/or C. trachomatis infection, compared with 13 of 37 women (35%) treated with cefoxitin-doxycycline (P = 0.004) (Table 2). Four of 38 women (11%) treated with ampicillin-sulbactam and 5 of 37 women (14%) treated with cefoxitin-doxycycline were HIV seropositive. Clinical and microbiologic responses to therapy: follow-up 3 to 4 weeks after treatment. Sixty-five women returned for at least one visit following the completion of therapy. Thirtythree had received ampicillin-sulbactam and 32 had received cefoxitin-doxycycline (Table 3). Among the women who received ampicillin-sulbactam, 10 (30%) had findings suggestive of persistent PID and required additional therapy. Among women who received cefoxitin-doxycycline, nine (28%) had persistent signs and symptoms necessitating additional antibiotic treatment (P = 0.94). Among the nine women with chlamydial infection who received ampicillinsulbactam, three clinically failed, four were clinically well or improved, and two did not return, although none were culture positive at the first follow-up. One of 22 women with gonococcal infections who were treated with ampicillin- TABLE 2. Etiologic agents isolated from the cervix at enrollment No. (%) for group Pathogen Ampicillin-sulbactam Cefoxitin-doxycycline (n = 38) (n = 37) N. gonorrhoeae alone 18 (47) 12 (32) C. trachomatis alone 5 (13) 1 (3) N. gonorrhoeae and 4 (11) 0 C. trachomatis Neither of above 11 (29) 24 (65) HIV (seropositivity) 4 (11) 5 (14) sulbactam remained culture positive at follow-up, as did 1 of 12 women treated with cefoxitin-doxycycline. Both of these failures to cure gonococcal infection occurred among women who denied having had sexual reexposure. Follow-up 5 to 6 weeks after treatment. Fifty-three patients were seen 5 to 6 weeks after the acute illness, including 25 treated with ampicillin-sulbactam and 28 treated with cefoxitin-doxycycline. This includes eight patients from the ampicillin-sulbactam group and nine from the cefoxitin-doxycycline group who had been retreated because of early clinical failure. The results for 37 patients who previously showed favorable early clinical responses are shown in Table 3. At this visit, 6 of 18 women (33%) who received ampicillinsulbactam and 4 of 19 women (21%) who received cefoxitindoxycycline had late clinical relapses and required additional antimicrobial therapy (P = 0.47). Among women initially infected with N. gonorrhoeae, none treated with ampicillin-sulbactam were culture positive at the late follow-up, compared with two of nine women treated with cefoxitin-doxycycline. Both gonococcal treatment failures with cefoxitin-doxycycline occurred among women who denied having had sexual reexposure. Among women initially infected with C. trachomatis, three treated with ampicillin-sulbactam were culture positive. Two of the three chlamydial treatment failures occurred in women who denied having had sexual reexposure. The one women with C. trachomatis infection randomly selected to receive cefoxitin-doxycycline was culture negative at both follow-up visits. Fertility outcome. Forty-nine women were evaluated for reproductive outcome, 20 women in the ampicillin-sulbactam group and 29 women in the cefoxitin-doxycycline group. Forty-four women underwent hysterosalpingography, and five had interim pregnancies (Table 4). Among women treated with ampicillin-sulbactam, 3 became pregnant and 11
4 1654 KOSSEIM ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 3. Clinical and microbiological results at follow-up visits Value for group Treatment Clinically Clinically unimproved N. gonorrhoeae culture C. trachomatis culture Clinically well improved or relapseda recurrently or recurrently or persistently positiveb persistently positive 2- to 3-wk follow-up Randomized ampicillin-sulbactam (n = 33) Randomized cefoxitin-doxycy cline (n = 32) 5- to 6-wk follow-upc Randomized ampicillin-sulbactam (n = 18) Randomized cefoxitin-doxycy cline (n = 19) a Unimproved at the 2- to 3-week follow-up and relapsed at the 5- to 6-week follow-up. b Persistently positive at the 2- to 3-week follow-up and recurrently positive at the 5- to 6-week follow-up. c Analysis is limited to those women who had favorable responses at the 2- to 3-week follow-up visit. had hysterosalpingograms which demonstrated at least one clearly patent tube. Three women (18%) showed bilateral distal tubal obstruction and three could not be evaluated because of cornual spasm and absence of filling of the fallopian tubes. Among women treated with cefoxitin-doxycycline, two became pregnant and 14 had hysterosalpingograms which showed at least one normal tubal anatomy; eight women (33%) had bilaterally abnormal tubes with distal obstruction as determined by radiography. Five hysterosalpingograms could not be evaluated because of bilateral tubal spasm at the comua which prevented tubal filling. Correlates of post-pid bilateral tubal obstruction. Fortynine women were evaluated regarding tubal outcome. This included 41 women from the comparative clinical trial and 8 women from the open-label study. Eleven women had bilateral obstruction as determined by hysterosalpingography and 38 had evidence of at least unilateral tubal patency (Table 5). Comparison of these two outcome groups shows that the finding of an adnexal mass at the time of enrollment was significantly associated with bilateral tubal obstruction at follow-up (P = 0.002). Women with bilateral tubal obstruction had marginally lower fertility than did women with tubal patency, since only 1 of 11 women with obstruction (9%) had been pregnant in the prior 18 months compared with 14 of 38 women (37%) with tubal patency (P = 0.08). Women with bilaterally obstructed tubes received ampicillin-sulbactam less often than did women with tubal patency (P = 0.15). Side effects. Overall, in the ampicillin-sulbactam-treated group, 1 of 51 patients developed a maculopapular, pruritic rash 4 days after the initiation of therapy and 24 patients Treatment TABLE 4. Pregnancy Fertility outcome No. (%) for group Hysterosalpingography Normal Abnormal Othera Ampicillin-sulbactam (18) 3 (n = 20) Cefoxitin-doxycycline (33) 5 (n = 29) a Results could not be evaluated. experienced some gastrointestinal disturbance (diarrhea, nausea, and/or vomiting). These side effects were mild. All side effects were tolerated without therapy being interrupted. In the cefoxitin-doxycycline-treated group, 4 women developed a rash and 16 complained of gastrointestinal symptoms. In three cases, gastrointestinal symptoms were severe enough to cause discontinuation of the antibiotic. DISCUSSION Although most women with acute PID are treated in an ambulatory setting, few studies are available to guide the choice of therapy. The determination of optimal therapy in this situation is an urgent priority and this is especially TABLE 5. Correlates of post-pid tubal obstruction Value (%) for group Characteristic Bilateral tubal Tubal p obstruction patency (n = 11) (n = 38) Age (yr) ± ± 3.6 Contraception: Current use of IUD 1 4 Ever used IUD 1 7 Current oral contraceptive 2 4 Palpable mass Past history of PID 2 7 Nulliparity 4 7 Mean gravidity 1.64 ± ± 1.8 Mean parity 1.36 ± ± 1.4 No. with parity of Mean time since past pregnancy 27 ± ± 22.0 (months) No. pregnant within last months Treatment with: Ampicillin-sulbactam 3 (27) 22 (58) 0.15 Cefoxitin-doxycycline 8 (73) 16 (42) Clinical treatment failure 6 22 Initial cervical isolation of: N. gonorrhoeae 5 (45) 10 (26) C. trachomatis 1 (9) 2 (5) Neither 5 (45) 24 (63) HIV seropositivity 0 5 (13)
5 VOL. 35, 1991 relevant for developing countries. The ideal treatment trial should involve laparoscopic verification, although this is not feasible in most outpatient settings. Both short-term clinical and microbiologic outcome measurements and longer-term reproductive outcome measurement should be determined, since the major shortcoming of most antimicrobial regimens is their effect on late PID sequela (6). We compared a 13-lactamase inhibitor (sulbactam) combined with ampicillin to a widely recommended regimen, cefoxitin-probenecid-doxycycline, in the treatment of 75 women with clinically diagnosed acute PID in a sexually transmitted disease clinic in Nairobi, Kenya. Ampicillinsulbactam was used alone because of its excellent in vitro activity against N. gonorrhoeae, members of the family Enterobacteriaceae, and genital anaerobes. Furthermore, clinical evidence suggested that it was useful among women with PIP-associated pyosalpinx (14). While,-lactam antibiotics are normally thought not to be useful for the treatment of C. trachomatis infection, Crombleholme et al. (11) reported that amoxicillin was highly effective in treating C. trachomatis infection among pregnant women. Other smaller trials also suggested that ampicillin-amoxicillin was effective in vivo in eradicating C. trachomatis (2, 15, 19-21). We therefore evaluated ampicillin-sulbactam alone. The short-term clinical cure rates and relapse rates were similar for both regimens. None of the differences were statistically significant. These clinical response rates are less than has been observed in other studies conducted in developed countries. Although we did not document the reason for the lower efficacy, it may relate to the poor performance of ampicillin-sulbactam for C. trachomatis infection and the suboptimal performance of cefoxitin-doxycycline for gonococcal and polymicrobial infection. We conclude that neither regimen is optimally effective for the management of outpatient PID in a developing country. Microbiologic cure rates of gonococcal infection were similar for the two regimens, with ampicillin-sulbactam failing to eradicate 1 of 22 gonococcal infections (5%) and cefoxitin-doxycycline failing to eradicate 1 of 12 gonococcal infections (8%). Two late reinfections or relapses of gonococcal infection occurred among women randomly selected to receive cefoxitin-doxycycline. Both women denied having had sexual reexposure. No late failures occurred among ampicillin-sulbactam-treated women. Ampicillin-sulbactam appeared to suppress rather than eradicate C. trachomatis infection, since 3 of 9 infected women who were monitored had late microbiologic relapse. Two of three recurrences occurred among women who denied having had sexual reexposure. Future studies of ampicillin-sulbactam treatment of acute PID should use doxycycline in combination with ampicillin-sulbactam. A major outcome measurement in the treatment of acute PID is the preservation of tubal function. The best way to determine this is to perform long-term (5 to 10 years) posttreatment follow-up of women, with monitoring of pregnancy rates (23). Such studies are extremely difficult to perform and are of necessity lengthy in duration. We used early posttreatment pregnancy rate or hysterosalpingographic appearance of tubal anatomy to estimate the effect of antimicrobial therapy on tubal function. Forty-nine women had a fertility outcome evaluation. We observed no significant difference in adverse reproductive outcome between the ampicillin-sulbactam-treated group and the cefoxitindoxycycline-treated group. Post-PID sequelae include chronic pelvic pain, tubal infertility, and ectopic pregnancy (24). The benchmark studies of TREATMENT OF PID 1655 Westrom (23) documented that post-pid sequelae occur in approximately 20% of treated women. Risk factors for post-pid sequelae include pyosalpinx and tubal ovarian abscess (7), C. trachomatis infection (7), C. trachomatis antibodies to a chlamydial hypersensitivity antigen (8), older age (23), prior PID (23), and nonuse of oral contraceptives during the current episode of PID (26). We compared some of these factors for the 11 women with post-pid tubal occlusion and the 38 women with evidence of tubal patency. We observed no difference in age, current use of oral contraceptive, or microbial etiology between the two groups. Women with bilateral tubal obstruction differed from women with tubal patency by more often having palpable adnexal masses at presentation (P = 0.002), tending to be subfertile (P = 0.08), and more often being treated with cefoxitin-doxycycline (P = 0.15). Although HIV seropositivity was relatively frequent (12%) among these women, this finding did not to correlate with post-pid tubal obstruction (P = 0.57). The observation that women with bilateral tubal obstruction may be subfertile suggests that tubal disease detected by hysterosalpingography may have antedated the current episode of PID. This seems possible, since tubal dysfunction is a risk factor both for recurrent PID and for tubal infertility (23). This finding suggests a potential limitation for the use of either hysterosalpingography or a second laparoscopy in the post-pid evaluation of tubal anatomy, since one is unable to determine whether structural damage antedated or followed the episode of acute PID. Restricting analysis to women with an initial episode of PID may reduce but not eliminate this bias because of the occurrence of "silent" PID. Fifty-one women underwent hysterosalpingography with periprocedural doxycycline prophylaxis. Five women experienced recurrence of pelvic pain following the procedure and required supplemental antibiotics. Symptoms rapidly resolved in four patients; one women became systemically ill, requiring hospital admission because of peritonitis and abscess formation. Following surgical drainage and antibiotic therapy, she eventually recovered. Post-PID women seem to be at a high risk of relapsing infection following hysterosalpingography. The use of radionuclide scanning with technetium-labeled human albumin microspheres (22) and of vaginal ultrasound examination (18) to study tubal function should be evaluated for their abilities to predict post-pid tubal dysfunction, as they may be more acceptable as short-term measurements of tubal anatomy. The results of this study need to be interpreted within the context of important deficiencies in the study design. The sample size was clearly insufficient to detect any real difference in the response rates between the two regimens. If the anticipated cure rate was 90% (as seems reasonable for the cefoxitin-doxycycline regimen on the basis of the data in reference 16) and a 15% difference in response rates was sought, 146 cases would be required in each arm of the study to achieve a significance of P < 0.05 and a power of 0.9 to exclude a c error. Future studies on the outpatient treatment of acute PID should attain sample sizes of this magnitude if important differences between regimens are to be found. In this study as well, randomization did not yield treatment groups comparable in major prognostic factors for post-pid tubal occlusion. For example, 71% of the patients in the ampicillin-sulbactam group had either N. gonorrhoeae or C. trachomatis infection, compared with only 35% of the cefoxitin-doxycycline group. Also, 5 of 37 cefoxitin-doxycycline-treated women (14%) had a palpable adnexal mass at presentation, compared with 1 of 38 women (3%) treated
6 1656 KOSSEIM ET AL. with ampicillin-sulbactam (P = 0.18); women treated with cefoxitin-doxycycline more frequently had a history of PID than did women treated with ampicillin-sulbactam (22 versus 11%, P = 0.15). On the basis of these data, we suggest that future studies using block randomization with stratification according to the presence or absence of adnexal mass and initial or recurrent episode of PID may be of benefit. ACKNOWLEDGMENTS We gratefully acknowledge G. Maitha for microbiologic assistance and R. Radesic for preparation of the manuscript. A research grant from Pfizer International supported this study. REFERENCES 1. Aral, S. O., W. D. Mosher, and W. Cates Self-reported pelvic inflammatory disease in the US: a common occurrence. Am. J. Public Health 75: Bowie, W. R., E. R. Alexander, and K. K. Holmes Eradication of Chlamydia trachomatis from the urethra of men with non-gonococcal urethritis by amoxicillin treatment. Sex. Transm. Dis. 8: Bowie, W. R., L. M. Manzon, C. J. Borrie-Hume, A. Fawcett, and H. D. Jones Efficacy of treatment regimens for lower urogenital Chlamydia trachomatis infections in women. Am. J. Obstet. Gynecol. 142: Bruhat, M. A., G. Le Bouedec, J. L. Pouly, G. Mage, and M. Canis Treatment of acute salpingitis with sulbactam/ ampicillin. Int. J. Gynaecol. Obstet. 2(Suppl.): Bruhat, M. A., J. L. Pouly, G. Le Bouedec, and G. Mage Treatment of acute salpingitis with sulbactam/ampicillin: comparison with cefoxitin. Drugs 31(Suppl. 2): Brunham, R. C Therapy of acute pelvic inflammatory disease: a critique of recent treatment trials. Am. J. Obstet. Gynecol. 148: Brunham, R. C., B. Binns, F. Gujon, D. Danforth, M. L. Kosseim, F. Rand, J. McDowell, and E. Rayner Etiology and outcome of acute pelvic inflammatory disease. J. Infect. Dis. 158: Brunham, R. C., I. W. Maclean, B. Binns, and R. W. Peeling Chlamydia trachomatis: its role in tubal infertility. J. Infect. Dis. 152: Cameron, D. W., J. N. Simonsen, L. J. D'Costa, A. R. Ronald, G. M. Maitha, M. N. Gakinya, M. Cheang, J. 0. Ndinya-Achola, P. Piot, R. C. Brunham, and F. A. Plummer Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet i: Crombleholme, W., D. Landers, M. Ohm-Smith, M. 0. Robbie, W. K. Hadley, V. DeKay, D. Dahrouge, and R. L. Sweet Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs 31(Suppl. 2): Cromblehohne, W. R., J. Schacter, M. Grossman, D. V. Landers, and R. L. Sweet Amoxicillin therapy for Chlamydia trachomatis in pregnancy. Obstet. Gynecol. 75: Falk, V Treatment of acute non-tuberculous salpingitis with antibiotics alone and in combination with glucocorticoids. Acta Obstet. Gynecol. Scand. 44(Suppl. 6):1-18. ANTIMICROB. AGENTS CHEMOTHER. 13. Gunning, H A comparison of parenteral sulbactam/ ampicillin versus clindamycin/gentamicin in the treatment of pelvic inflammatory disease. Drugs 31(Suppl. 2): Hemsell, D. L., M. C. Heard, P. G. Hemsell, and B. J. Nobles Sulbactam/ampicillin versus cefoxitin for uncomplicated and complicated acute pelvic inflammatory disease. Drugs 35(Suppl. 7): Johannison, G., A. Sernryd, and E. Lycke Susceptibility of Chlamydia trachomatis to antibiotics in vitro and in vivo. Sex. Transm. Dis. 6: Lester, S. C., M. Del Pilar Pla, F. Wang, I. P. Schael, H. Jiang, and T. F. O'Brien The carriage of Escherichia coli resistant to antimicrobial agents by healthy children in Boston, in Caracas, Venezuela, and in Qin Pu, China. N. Engl. J. Med. 323: Obwegeser, J., J. Kunz, J. Wust, G. Schar, R. Steiner, and W. Buchi Clinical efficacy of amoxicillin/clavulanate in laparoscopically confirmed salpingitis. J. Antimicrob. Chemother. 24(Suppl. B): Paavonen, J., B. Cacciatore, A. Leminen, S. Ingman-Friberg, and P. Yeostalo Outpatient diagnosis of pelvic inflammatory disease, p In W. R. Bowie, H. D. Caldwell, R. P. Jones, P. A. Mardh, G. L. Ridgway, J. Schachter, W. E. Stamm, and M. G. Ward (ed.), Proceedings of the Seventh International Symposium on Human Chlamydial Infections. Cambridge University Press, Cambridge. 19. Peterson, H. B., E. I. Galaid, and J. M. Zenilman Pelvic inflammatory disease: review of treatment options. Rev. Infect. Dis. 12(Suppl. 6):S656-S Pittaway, D. E., A. C. Winfield, W. Maxson, J. Daniell, C. Herbert, and A. C. Wentz Prevention of acute pelvic inflammatory disease after hysterosalpingography: effect of doxycycline prophylaxis. Am. J. Obstet. Gynecol. 147: Stephens, R. S., C. C. Kuo, and M. R. Tam Sensitivity of immunofluorescence with monoclonal antibodies for detection of Chlamydia trachomatis inclusion in cell culture. J. Clin. Microbiol. 16: Stone, S. C., M. McCalley, P. Braunstein, and R. Egbert Radionuclide evaluation of tubal function. Fertil. Steril. 43: Westrom, L Effect of acute pelvic inflammatory disease on fertility. Am. J. Obstet. Gynecol. 121: Westrom, L Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am. J. Obstet. Gynecol. 138: WHO Expert Committee on Venereal Diseases and Treponematoses Sixth report. Technical report series no. 736, p World Health Organization, Geneva. 26. Wolner-Hanssen, P., D. A. Eschenbach, J. Paavonen, N. Kiviat, C. E. Stevens, C. Critchlow, T. DeRouen, and K. K. Holmes Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA 263: Wolner-Hanssen, P., J. Paavonen, N. Kiviat, M. Young, D. A. Eschenbach, and K. K. Holmes Outpatient treatment of pelvic inflammatory disease with cefoxitin and doxycycline. Obstet. Gynecol. 71:
Gynaecology. Pelvic inflammatory disesase
Gynaecology د.شيماءعبداألميرالجميلي Pelvic inflammatory disesase Pelvic inflammatory disease (PID) is usually the result of infection ascending from the endocervix causing endometritis, salpingitis, parametritis,
More informationAmpicillin/Sulbactam Vs. Cefoxitin for the Treatment
Infectious Diseases in Obstetrics and Gynecology 5:319-325 (1997) (C) 1998 Wiley-Liss, Inc. Ampicillin/Sulbactam Vs. Cefoxitin for the Treatment of Pelvic Inflammatory Disease Joseph G. Jemsek* and Frank
More informationPelvic Inflammatory Disease (PID) Max Brinsmead PhD FRANZCOG July 2011
Pelvic Inflammatory Disease (PID) Max Brinsmead PhD FRANZCOG July 2011 This talk What is Pelvic Inflammatory Disease? Why it is important How it is spread Diagnosis Treatment Prevention What is PID? Inflammation
More informationMANAGEMENT OF ACUTE PELVIC INFLAMMATORY DISEASE
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION C: GUIDELINES RELEVANT TO GYNAECOLOGY 6.1 ABDOMINAL / PELVIC PAIN 6.1 ACUTE PAIN Authorised by: OGCCU 6.1.3 TREATMENT 6.1.3.1 MANAGEMENT OF
More informationPelvic Inflammatory Disease and Involuntary Infertility: Prospective Pilot Observations
Virginia Commonwealth University VCU Scholars Compass Obstetrics and Gynecology Publications Dept. of Obstetrics and Gynecology 1995 Pelvic Inflammatory Disease and Involuntary Infertility: Prospective
More informationA Prospective Study Of Comparison Of Efficacy Of Two Combination Treatment Regimens In Syndromic Treatment Of Pelvic Inflammatory Disease
ISPUB.COM The Internet Journal of Gynecology and Obstetrics Volume 5 Number 2 A Prospective Study Of Comparison Of Efficacy Of Two Combination Treatment Regimens In Syndromic Treatment Of Pelvic Inflammatory
More informationReview Article Treatment of Acute Pelvic Inflammatory Disease
Hindawi Publishing Corporation Infectious Diseases in Obstetrics and Gynecology Volume 2011, Article ID 561909, 13 pages doi:10.1155/2011/561909 Review Article Treatment of Acute Pelvic Inflammatory Disease
More informationInfertility Following Pelvic Inflammatory Disease
Infectious Diseases in Obstetrics and Gynecology 7:145-152 (1999) (C) 1999 Wiley-Liss, Inc. Infertility Following Pelvic Inflammatory Disease A.J. Pavletic, 1. P. W61ner-Hanssen, 2 J. Paavonen, 3 S.E.
More informationTreatment of Uncomplicated Chlamydia trachomatis Cervicitis
Infectious Diseases in Obstetrics and Gynecology 5:18-22 (1997) (C) 1997 Wiley-Liss, Inc. Evaluation of 3-Day Course of Doxycycline for the Treatment of Uncomplicated Chlamydia trachomatis Cervicitis Mark
More informationRisk of Sequelae after Chlamydia trachomatis Genital Infection in Women
SUPPLEMENT ARTICLE Risk of Sequelae after Chlamydia trachomatis Genital Infection in Women Catherine L. Haggerty, 1 Sami L. Gottlieb, 2 Brandie D. Taylor, 1 Nicola Low, 4 Fujie Xu, 2 and Roberta B. Ness
More informationCASE-BASED SMALL GROUP DISCUSSION MHD II SESSION VI. Friday, MARCH 20, 2015 STUDENT COPY
MHD II, Session VI, STUDENT Copy Page 1 CASE-BASED SMALL GROUP DISCUSSION MHD II SESSION VI Friday, MARCH 20, 2015 STUDENT COPY Resource for cases: ACP Medicine (Scientific American Medicine) - Vaginitis
More informationCASE-BASED SMALL GROUP DISCUSSION MHD II SESSION 6. Friday, MARCH 18, 2016 STUDENT COPY
MHD II, Session 6, STUDENT Copy Page 1 CASE-BASED SMALL GROUP DISCUSSION MHD II SESSION 6 Friday, MARCH 18, 2016 STUDENT COPY Resource for cases: ACP Medicine (Scientific American Medicine) - Vaginitis
More informationClinical Study Tuboovarian Abscesses: Is Size Associated with Duration of Hospitalization & Complications?
Hindawi Publishing Corporation Obstetrics and Gynecology International Volume 2010, Article ID 847041, 5 pages doi:10.1155/2010/847041 Clinical Study Tuboovarian Abscesses: Is Size Associated with Duration
More informationMedicaid Family Planning Waiver Services CPT Codes and ICD-10 Diagnosis Codes
CPT Code Description of Covered Codes Evaluation and Management 99384FP 99385FP Family planning new visit 99386FP 99394FP 99395FP Family planning established visit 99396FP 99401FP HIV counseling (pre-test)
More informationInfertility after acute salpingitis with special reference to Chlamydia trachomatis
FERTILITY AND STERILITY Copyright" 1983 The American Fertility Society Printed in U.SA. Infertility after acute salpingitis with special reference to Chlamydia trachomatis Lars Svensson, M.D. *t Per-Anders
More informationTHE EFFECTIVENESS FOR TREATMENT OF PELVIC INFLAMMATORY DISEASE ON LONG-TERM SEQUELAE. Gail Trautmann. MA, Ball State University, 2001
THE EFFECTIVENESS FOR TREATMENT OF PELVIC INFLAMMATORY DISEASE ON LONG-TERM SEQUELAE by Gail Trautmann BA, State University of New York at Binghamton, 1999 MA, Ball State University, 2001 Submitted to
More informationSusceptibility of Pathogens Associated with Pelvic Inflammatory Disease to Antimicrobial Agents in Western U.P. India
ISSN: 2319-7706 Volume 4 Number 7 (2015) pp. 192-198 http://www.ijcmas.com Original Research Article Susceptibility of Pathogens Associated with Pelvic Inflammatory Disease to Antimicrobial Agents in Western
More informationINTRAUTERINE DEVICES AND INFECTIONS. Tips for Evaluation and Management
INTRAUTERINE DEVICES AND INFECTIONS Tips for Evaluation and Management Objectives At the end of this presentation, the participant should be able to: 1. Diagnose infection after IUD placement 2. Provide
More informationPelvic inflammatory disease An approach for GPs in Australia
THEME: STIs Pelvic inflammatory disease An approach for GPs in Australia BACKGROUND Pelvic inflammatory disease (PID) is a treatable condition with serious long term sequelae. Due to the wide spectrum
More informationFollow this and additional works at:
Virginia Commonwealth University VCU Scholars Compass Obstetrics and Gynecology Publications Dept. of Obstetrics and Gynecology 1998 Clinical Utility of CA125 Levels in Predicting Laparoscopically Confirmed
More informationPELVIC INFLAMMATORY. The Most Serious and Costly Bacterial Sexually BOB CARUTHERS, CST, PHD
PELVIC INFLAMMATORY The Most Serious and Costly Bacterial Sexually BOB CARUTHERS, CST, PHD CE Examination Category 3 DISEASE Transmitted Disease INTRODUCTION Pelvic inflammatory disease (PID) is a global
More informationAcute Salpingitis. Fallopian Tubes. Uterus
Acute Salpingitis Introduction Acute salpingitis is a type of infection that affects the Fallopian tubes. The Fallopian tubes carry eggs from the ovaries to the uterus. Acute salpingitis is one of the
More informationInflammatory Disease
Infectious Diseases in Obstetrics and Gynecology 3:56-59 (1995) (C) 1995 Wiley-Liss, Inc. Endometrial Cultures in Acute Pelvic Inflammatory Disease Soheil Amin-Hanjani and Ashwin Chatwani Department of
More informationPELVIC INFLAMMATORY DISEASE (PID)
PELVIC INFLAMMATORY DISEASE (PID) DEFINITION Pelvic inflammatory disease is an infection of the female upper genital tract that involves any combination of the uterus, endometrium, ovaries, fallopian tubes,
More informationBiology 3201 Unit 2 Reproduction: Sexually Transmitted Infections (STD s/sti s)
Biology 3201 Unit 2 Reproduction: Sexually Transmitted Infections (STD s/sti s) STI s once called venereal diseases More than 20 STIs have now been identified most prevalent among teenagers and young adults.
More informationBursting Pelvic Inflammatory Disease.
www.infertiltysolutionsng.info/blog Disclaimer The information in this book is provided for educational purposes only and is not intended to treat, diagnose or prevent any disease. The information in this
More informationInfections with Neisseria gonorrhoeae and
Infections with Neisseria gonorrhoeae and Chlamydia trachomatis in women with acute salpingitis Genitourin Med 1985;61:179-84 G B KRISTENSEN,* A C BOLLERUP,t K LIND,* P-A MARDH, P LADEHOFF,* S LARSEN,*
More informationPelvic Inflammatory Disease
Pelvic Inflammatory Disease GRAND ROUNDS 03/07/18 HOLLY MONTGOMERY, MD Outline Pathogenesis Microbiology Risk Factors Clinical Manifestation Diagnosis Long Term Complications Treatment Review Pathogenesis
More informationfor Treatment of Chlamydial Infection in Pregnancy
Infectious Diseases in Obstetrics and Gynecology 3:241-244 (1995) (C) 1996 Wiley-Liss, Inc. Randomized Trial of Erythromycin and Azithromycin for Treatment of Chlamydial Infection in Pregnancy Marc F.
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/14885
More informationEctopic pregnancy and antibodies to Chlamydia trachomatis*
FERTILITY AND STERILITY Copyright 1985 The American Fertility Society Vol. 44, No.3, Septemher 1985 Prinred in U.SA. Ectopic pregnancy and antibodies to Chlamydia trachomatis* Lars Svensson, M.D.t Per-Anders
More informationThe objectives of this presentation are; to increase awareness of the issue of antimicrobial resistant gonorrhea, and to inform primary care and
1 Antimicrobial resistant gonorrhea is an emerging public health threat that needs to be addressed. Neisseria gonorrhoeae is able to develop resistance to antimicrobials quickly. Effective antibiotic stewardship
More informationBursting Pelvic Inflammatory Disease.
www.infertiltysolutionsng.info/blog Disclaimer The information in this book is provided for educational purposes only and is not intended to treat, diagnose or prevent any disease. The information in this
More informationManagement of Gonorrhea in Adolescents and Adults in the United States
SUPPLEMENT ARTICLE Management of Gonorrhea in Adolescents and Adults in the United States Sarah Kidd 1 and Kimberly A. Workowski 1,2 1 Division of STD Prevention, Centers for Disease Control and Prevention,
More informationSalpingitis : laparoscopy roles
Salpingitis : laparoscopy roles Dr AS AZUAR We need a relevant way to diagnose because Epidemiology Public health matter -130.000 cases / year - 15.000 cases of tubal infertility - Pb linked to complications/
More informationJulie Nelson RNC/WHNP-BC Epidemiology NURS 6313
Julie Nelson RNC/WHNP-BC Epidemiology NURS 6313 Chlamydia Most frequently reported bacterial STI in the US In 2006, In U.S. 1,030,911 cases were reported. Estimated 2,291,000 infections in 14-39 year olds.
More informationInpatient Treatment for Uncomplicated and Complicated Acute Pelvic Inflammatory Disease: Ampicillin/Sulbactam Vs. Cefoxitin
Infectious Diseases in Obstetrics and Gynecology I" 13-19 (1993) (C) 199 Wiley-Liss, Inc. Inpatient Treatment for Uncomplicated and Complicated Acute Pelvic Inflammatory Disease: Ampicillin/Sulbactam Vs.
More informationSexually Transmitted Diseases. Summary of CDC Treatment Guidelines
DC 2015 Sexually Transmitted Diseases Summary of CDC Treatment Guidelines These summary guidelines reflect the June 2015 update to the 2010 CDC Guidelines for Treatment of Sexually Transmitted Diseases.
More informationUnsuspected chronic pelvic inflammatory disease in the infertile female
FERTILITY AND STERILITY Copyright c 1983 The American Fertility Society Printed in U.SA. Unsuspected chronic pelvic inflammatory disease in the infertile female David L. Rosenfeld, M.D. * Steven M. Seidman,
More informationPELVIC INFLAMMATORY. The Most Serious and Costly Bacterial Sexually BOB CARUTHERS, CST, PHD
PELVIC INFLAMMATORY The Most Serious and Costly Bacterial Sexually BOB CARUTHERS, CST, PHD CE Examination Category 3 DISEASE Transmitted Disease INTRODUCTION Pelvic inflammatory disease (PID) is a global
More informationDual Therapy: Symptoms and Screening:
5. Gonorrhea Gonorrhea is caused by Neisseria gonorrhoeae, a bacterium that can grow and multiply in the warm, moist areas of the reproductive tract, including the cervix (opening to the womb), uterus
More informationPELVIC INFLAMMATORY DISEASE (PID) SALIM ABDUL-RAZAK (INTERN RADIOGRAPHER) TAMALE TEACHING HOSPITAL
PELVIC INFLAMMATORY DISEASE (PID) SALIM ABDUL-RAZAK (INTERN RADIOGRAPHER) TAMALE TEACHING HOSPITAL OBJECTIVES Definition of PID Prevalence rate of PID Causes of PID Symptoms of PID Risk factors Investigations
More informationSexually Transmi/ed Diseases
Sexually Transmi/ed Diseases Chapter Fourteen 2013 McGraw-Hill Higher Education. All rights reserved. Also known as sexually transmitted infections The Major STDs (STIs) HIV/AIDS Chlamydia Gonorrhea Human
More informationStephanie. STD Diagnosis and Treatment. STD Screening for Women. Physical Exam. Cervix with discharge from os
STD Diagnosis and Treatment Ina Park, MD, MS STD Control Branch, California Department of Public Health California STD/HIV Prevention Training Center Stephanie 23 year-old female presents for contraception,
More informationA randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy
Infect Dis Obstet Gynecol 2001;9:197 202 A randomized trial of azithromycin versus amoxicillin for the treatment of Chlamydia trachomatis in pregnancy Jennifer Kacmar, Emily Cheh, Andrea Montagno and Jeffrey
More informationRapid Diagnosis of Chlamydial Infection in Young Women at Reproductive Age
Feb. 2012, Volume 9, No. 2 (Serial No. 87), pp. 112 116 Journal of US-China Medical Science, ISSN 1548-6648, USA D DAVID PUBLISHING Rapid Diagnosis of Chlamydial Infection in Young Women at Reproductive
More informationSexually Transmitted Diseases. Chlamydial. infection. Questions and Answers
Sexually Transmitted Diseases Chlamydial infection Questions and Answers What is chlamydial infection? It is a sexually transmitted infection caused by the bacteria Chlamydia trachomatis, being one of
More informationSexually transmitted infections (in women)
Sexually transmitted infections (in women) Timothy Kremer, MD Assistant Professor, Department of Obstetrics and Gynecology University of North Texas Health Science Center Last official CDC guidelines:
More informationwhich may be secondary to associated cervicitis and endometritis.
Pelvic inflammatory disease - Management View full scenario How should I diagnose pelvic inflammatory disease? A diagnosis of pelvic inflammatory disease (PID) should be made on clinical grounds. o Negative
More informationGenital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management. William M. Geisler M.D., M.P.H. University of Alabama at Birmingham
Genital Chlamydia and Gonorrhea Epidemiology, Diagnosis, and Management William M. Geisler M.D., M.P.H. University of Alabama at Birmingham Chlamydia and Gonorrhea Current Epidemiology Chlamydia Epidemiology
More information9. Sorting out pelvic inflammatory disease
Sorting out STIs 31 PART-WORK The ninth in a series of articles on diagnosing and managing genitourinary infections 9. Sorting out pelvic inflammatory disease NINA VON KNORRING AND JANET WILSON Pelvic
More informationPrevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections in Greenland A seroepidemiological study
Br J Vener Dis 8; :-. Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae infections in Greenland A seroepidemiological study P-A MARDH,* I LIND,t E ROM,* AND A-L ANDERSEN* rom the *Institute
More informationOriginal Study. Culture of Non-Genital Sites Increases the Detection of Gonorrhea in Women
J Pediatr Adolesc Gynecol (2010) 23:246e252 Original Study Culture of Non-Genital Sites Increases the Detection of Gonorrhea in Women Courtney M. Giannini 1, Hye K. Kim, BS 1, Jonathan Mortensen 3, Joel
More informationRichmond, Virginia. I ve have this terrible pain
Acute Pelvic Pain A Practical Approach Christine Isaacs, MD Associate Professor Department of Obstetrics & Gynecology Virginia Commonwealth University School of Medicine Richmond, VA Richmond, Virginia
More information25/02/2016. New onset low abdominal pain in women of reproductive age. New onset low abdominal pain: why it matters?
New onset in women of reproductive age Dr Deborah Bateson Medical Director Family Planning NSW Chair Australasian Sexual Health Alliance why it matters? Can be fatal (consider ectopic pregnancy in all
More information6/11/15. BACTERIAL STDs IN A POST- HIV WORLD. Learning Objectives. How big a problem are STIs in the U.S.?
BACTERIAL STDs IN A POST- HIV WORLD Tracey Graney, PhD, MT(ASCP) Monroe Community College Learning Objectives Describe the epidemiology and incidence of bacterial STDs in the U.S. Describe current detection
More informationMicrobiological, epidemiological and clinical
26 Genitourin Med 1991;67:26-31 Microbiological, epidemiological and clinical correlates of vaginal colonisation by MAobiluncus species S L Hillier, C W Critchlow, C E Stevens, M C Roberts, P Wolner-Hanssen,
More informationDuration of Persistence of Gonococcal DNA Detected by Ligase Chain Reaction in Men and Women following Recommended Therapy for Uncomplicated Gonorrhea
JOURNAL OF CLINICAL MICROBIOLOGY, Oct. 2002, p. 3596 3601 Vol. 40, No. 10 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.10.3596 3601.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.
More informationAbdominal pain for evaluation. Dr Sanket Sontakke (DNB paediatrics 1st yr, Apollo children s hospital) GUIDE: Dr Shyamala J
Abdominal pain for evaluation Dr Sanket Sontakke (DNB paediatrics 1st yr, Apollo children s hospital) GUIDE: Dr Shyamala J 13 year old girl presenting with Fever since 3 days Pain abdomen since 3 days
More informationInfection with Chlamydia trachomatis is
In Women: A Comparison of Three Sets of Criteria By Jeanne M. Marrazzo, David Fine, Connie L. Celum, Susan DeLisle and H. Hunter Handsfield Selective screening has been associated with marked declines
More informationAnswers to those burning questions -
Answers to those burning questions - Ann Avery MD Infectious Diseases Physician-MetroHealth Medical Center Assistant Professor- Case Western Reserve University SOM Medical Director -Cleveland Department
More informationTHE ROLE OF DELAYED CARE SEEKING AND TOLL-LIKE RECEPTORS IN PELVIC INFLAMMATORY DISEASE AND ITS SEQUELAE. Brandie DePaoli Taylor
THE ROLE OF DELAYED CARE SEEKING AND TOLL-LIKE RECEPTORS IN PELVIC INFLAMMATORY DISEASE AND ITS SEQUELAE by Brandie DePaoli Taylor BS, California University of Pennsylvania, 2006 MPH, University of Pittsburgh,
More information4. Chlamydia. Treatment: Treating infected patients prevents further transmission to sex partners. In addition, treatment of chlamydia in pregnant
Photomicrograph of Chlamydia trachomatis, taken from a urethral scrape. 4. Chlamydia Chlamydia trachomatis infection is the most commonly reported sexually transmitted disease (STD) in the United States,
More informationTUBAL PLASTIC SURGERY is an accepted form of therapy in the treatment
Tubal Plastic Surgery ADNAN MROUEH, M.D., ROBERT H. GLASS, M.D., and C. LEE BUXTON, M.D. TUBAL PLASTIC SURGERY is an accepted form of therapy in the treatment of infertility. However, reports have differed
More informationSexual behavior survey and screening for chlamydia and gonorrhea in university students in South Korea
Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology1442-20422005 Blackwell Publishing Asia Pty LtdFebruary 2005122187193Original ArticleChlamydia and gonorrhea in students in South KoreaS-J
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More informationTimby/Smith: Introductory Medical-Surgical Nursing, 9/e
Timby/Smith: Introductory Medical-Surgical Nursing, 9/e Chapter 62: Caring for Clients With Sexually Transmitted Diseases Slide 1 Epidemiology Introduction Study of the occurrence, distribution, and causes
More informationTrends in Reportable Sexually Transmitted Diseases in the United States, 2007
Trends in Reportable Sexually Transmitted Diseases in the United States, 2007 National Surveillance Data for Chlamydia, Gonorrhea, and Syphilis Sexually transmitted diseases (STDs) remain a major public
More informationChlamydia trachomatis infection in women with secondary infertility
Chlamydia trachomatis infection in women with secondary infertility Abida Malik, M.D., a Suchitra Jain, M.D., a Meher Rizvi, M.D., a Indu Shukla, M.D., a and Seema Hakim, M.D. b a Department of Microbiology,
More informationNewest Approaches to Treatment of Pelvic Inflammatory Disease: A Review of Recent Randomized Clinical Trials
REVIEW ARTICLE Newest Approaches to Treatment of Pelvic Inflammatory Disease: A Review of Recent Randomized Clinical Trials Catherine L. Haggerty and Roberta B. Ness University of Pittsburgh, Pittsburgh,
More informationPatterns of adnexal inflammatory damage: Chlamydia, the intrauterine device, and history of pelvic inflammatory disease*
FERTILITY AND STERILITY Copyright 1984 The American Fertility Society Printed in U.SA. Patterns of adnexal inflammatory damage: Chlamydia, the intrauterine device, and history of pelvic inflammatory disease*
More informationDisclosures. STD Screening for Women. Chlamydia & Gonorrhea. I have no disclosures or conflicts of interest to report.
Disclosures Management of STIs: Challenges in Practice I have no disclosures or conflicts of interest to report. Alison O. Marshall, MSN, FNP-C Associate Professor of Practice & Director of the Family
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Pelvic Inflammatory Disease and Salpingitis: incidence of primary and repeat episodes in England Price, Malcolm; Ades, AE; Welton, N; Simms, I; Horner, PJ DOI: 10.1017/S0950268816002065 License: None:
More informationChlamydia Curriculum. Chlamydia. Chlamydia trachomatis
Chlamydia Chlamydia trachomatis 1 Learning Objectives Upon completion of this content, the learner will be able to: 1. Describe the epidemiology of chlamydial infection in the U.S. 2. Describe the pathogenesis
More informationCost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis Genc M, Mardh P A
Cost-effective treatment of uncomplicated gonorrhoea including co-infection with Chlamydia trachomatis Genc M, Mardh P A Record Status This is a critical abstract of an economic evaluation that meets the
More informationReview on the outpatient treatment for pelvic inflammatory disease, what is the best for Hong Kong?
Hong Kong Journal of Emergency Medicine Review on the outpatient treatment for pelvic inflammatory disease, what is the best for Hong Kong? SW Kung and MH Ng Pelvic inflammatory disease is an important
More informationClinical Characteristics Associated with Antibiotic Treatment Failure for Tuboovarian Abscesses
Clinical Characteristics Associated with Antibiotic Treatment Failure for Tuboovarian Abscesses The Harvard community has made this article openly available. Please share how this access benefits you.
More informationEffect of Blind Passage and Multiple Sampling on Recovery of Chlamydia trachomatis from Urogenital Specimens
JOURNAL OF CLINICAL MICROBIOLOGY, Dec. 1986, p. 1029-1033 0095-1137/86/121029-05$02.00/0 Copyright 1986, American Society for Microbiology Vol. 24, No. 6 Effect of Blind Passage and Multiple Sampling on
More informationMYCOPLASMA GENITALIUM: CLINICAL CHARACTERISTICS, RISK FACTORS AND ADVERSE PREGNANCY OUTCOME. Vanessa L. Short. BS, Pennsylvania State University, 2002
MYCOPLASMA GENITALIUM: CLINICAL CHARACTERISTICS, RISK FACTORS AND ADVERSE PREGNANCY OUTCOME by Vanessa L. Short BS, Pennsylvania State University, 2002 MPH, University of Pittsburgh, 2005 Submitted to
More informationCortisone in the Treatment of Tubal Occlusion Caused by Healed Genital Tuberculosis
Cortisone in the Treatment of Tubal Occlusion Caused by Healed Genital Tuberculosis ISAC HALBRECHT, M.D. THERE IS a general agreement on the importance of the tubal factor in sterility. In certain geographic
More informationPersistence of Chlamydial Antibodies
JOURNAL OF CLINICAL MICROBIOLOGY, May 1986, p. 924-928 0095-1137/86/050924-05$02.00/0 Copyright 1986, American Society for Microbiology Vol. 23, No. 5 Persistence of Chlamydial Antibodies after Pelvic
More informationPrevalence and Determinants of Neisseria Gonorrhea and Chlamydia Trachomatis Infections in Patients with Pelvic Inflammatory Disease at Lusaka, Zambia
Medical Journal of Zambia, Vol. 39,. 4 (212) ORIGINAL PAPER Prevalence and Determinants of Neisseria Gonorrhea and Chlamydia Trachomatis Infections in Patients with Pelvic Inflammatory Disease at Lusaka,
More informationISPUB.COM. Chlamydia in female reproductive tract. D Pandey, J Shetty, M Pai, Pratapkumar INTRODUCTION BURDEN OF SUFFERING MICROBIOLOGICAL ASPECT
ISPUB.COM The Internet Journal of Infectious Diseases Volume 7 Number 1 Chlamydia in female reproductive tract D Pandey, J Shetty, M Pai, Pratapkumar Citation D Pandey, J Shetty, M Pai, Pratapkumar. Chlamydia
More informationSexually Transmitted Disease Treatment Tables
Sexually Transmitted Disease Treatment Tables Federal Bureau of Prisons Clinical Practice Guidelines June 2011 Clinical guidelines are made available to the public for informational purposes only. The
More informationInformation for Informed Consent for Insertion of a Mirena IUD
Information for Informed Consent for Insertion of a Mirena IUD What is an IUD (intrauterine Device)? An intrauterine device (IUD) is a plastic device that is placed into your uterus to prevent pregnancy.
More informationPID and Pelvic TB Ina S. Irabon, MD, FPOGS, FPSRM, FPSGE
PID and Pelvic TB Ina S. Irabon, MD, FPOGS, FPSRM, FPSGE Obstetrics and Gynecology Reproductive Endocrinology and Infertility Laparoscopy and Hysteroscopy Main reference Comprehensive Gynecology 7 th edition,
More informationSEXUALLY TRANSMITTED DISEASES TREATMENT GUIDELINES (Part 1 of 5)
SEXUALLY TRANSMITTED DISEASES TREATMENT GUIDELINES (Part 1 of 5) BACTERIAL VAGINOSIS 1 clindamycin cream 2 Cleocin Vaginal Cream 2% vaginal cream Adults: 1 applicatorful at bedtime for 7 days metronidazole
More informationGonococcal Infection- Treatment Consideration
Gonococcal Infection- Treatment Consideration First generation cephalasporin allergy in 5-10% of patients with PCN allergy Contraindicated in those with a severe reaction Anaphylaxis Stevens Johnson syndrome
More informationNothing to disclose.
Update on Diagnosis and Treatment Lisa Winston, MD University of California, San Francisco/ Zuckerberg San Francisco General Nothing to disclose. 1 This talk will be a little depressing Rising incidence
More informationFamily Planning Eligibility Program
INDIANA HEALTH COVERAGE PROGRAMS PROVIDER REFERENCE M ODULE Family Planning Eligibility Program L I B R A R Y R E F E R E N C E N U M B E R : P R O M O D 0 0 0 5 3 P U B L I S H E D : N O V E M B E R 2
More informationImmunodiagnosis of Sexually Transmitted Disease
THE YALE JOURNAL OF BIOLOGY AND MEDICINE 58 (1985), 443-452 Immunodiagnosis of Sexually Transmitted Disease JULIUS SCHACHTER, Ph.D. Department oflaboratory Medicine, University of California, San Francisco,
More informationHow is it transferred?
STI s What is a STI? It is a contagious infection that is transferred from one person to another through sexual intercourse or other sexually- related behaviors. How is it transferred? The organisms live
More information7/2/15. Approach to imaging of pelvic pain. Acute pelvic pain. Chronic pelvic pain. Dysmenorrhea
I have no financial rela.onships to disclose. Approach to imaging of pelvic pain To emphasize the importance of ultrasound as the imaging modality of choice for the most commonly presen6ng diagnoses in
More informationSTI Treatment Guidelines. Teodora Wi. Training Course in Sexual and Reproductive Health Research
Teodora Wi Geneva, 28 August 2017 STI Treatment Guidelines Teodora Wi Training Course in Sexual and Reproductive Health Research 2017 Twitter @HRPresearch 1 STI treatment guidelines Neisseria gonorrhoeae
More informationChlamydia trachomatis antibody titers and hysterosalpingography in predicting tubal disease in infertility patients
FERTILITY AND STERILITY Copyright c 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Chlamydia trachomatis antibody titers and hysterosalpingography in predicting tubal disease
More information1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.
1 2 1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S. The contraceptive action of all IUDs is mainly in the uterine cavity. The major effect
More informationChronic Pelvic Pain. AP099, December 2010
AP099, December 2010 Chronic Pelvic Pain Pain in the pelvic area that lasts for 6 months or longer is called chronic pelvic pain. An estimated 15 20% of women aged 18 50 years have chronic pelvic pain
More informationInstruction for the patient
WS 4 Case 3 STI and IUD Your situation Instruction for the patient You are 32 years old, divorced and have one child; you have just started a new relationship You underwent surgical resection of the left
More informationSTI control. Dr. Jane Morgan Hamilton Sexual Health Clinic
STI control Dr. Jane Morgan Hamilton Sexual Health Clinic Overview STI control in theory NZ s reality Where to from here? STI control framework R0=ßcD R0 = reproductive rate; the rate at which infection
More informationChronic Pelvic Pain. Bridget Kamen, MD Obstetrics and Gynecology, Confluence Health. I have no disclosures
Chronic Pelvic Pain Bridget Kamen, MD Obstetrics and Gynecology, Confluence Health I have no disclosures Objectives A little epidemiology Understand there are both gynecologic and non-gynecologic causes
More information